logo

ENSC

Ensysce Biosciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 4
Revenue Plunges
EPS Below Expectations
Revenue Below Expectations
Revenue Keeps Dropping

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About ENSC

Ensysce Biosciences, Inc.

A clinical stage pharmaceutical company seeking to develop innovative solutions for severe pain relief while reducing the fear of and the potential for misuse, abuse, and overdose

Biological Technology
Invalid Date
07/02/2021
NASDAQ Stock Exchange
7
12-31
Common stock
7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037
--
Ensysce Biosciences, Inc., was incorporated in Delaware in April 2003. The company is a clinical-stage biotechnology company that leverages its proprietary technology platform to develop safer prescription drugs. Using its trypsin-activated abuse protection and multidrug abuse resistance platform, the company is developing a new class of powerful, tamper-proof opioids that can prevent drug abuse and overdose. Ensysce's products are expected to provide a safer option to treat severe pain and help prevent deaths from opioid abuse, thereby reducing human and economic costs.

Company Financials

EPS

ENSC has released its 2024 Q4 earnings. EPS was reported at -2.90, versus the expected -1.95, missing expectations. The chart below visualizes how ENSC has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ENSC has released its 2024 Q4 earnings report, with revenue of 1.30M, reflecting a YoY change of 153.12%, and net profit of -3.56M, showing a YoY change of -1.71%. The Sankey diagram below clearly presents ENSC’s revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime